Open Source Securities released a research report on April 19 stating that it gave the adopted shares (301122.SZ) a purchase rating. The main reasons for the rating include: 1) the size of the injection/puncture market is growing steadily, and overseas export pressure urgently needs to be resolved; 2) the medical+vettic+laboratory consumables troika, which drives rapid growth in performance due to technology+category+production capacity. (Mainichi Keizai Shimbun)
开源证券4月19日发布研报称，给予采纳股份（301122.SZ）买入评级。评级理由主要包括：1）注射穿刺市场规模稳定增长，海外出口压力亟需化解；2）医用+兽用+实验室耗材三驾马车，技术+品类+产能拉动业绩快速增长。（每日经济新闻）
Open Source Securities released a research report on April 19 stating that it gave the adopted shares (301122.SZ) a purchase rating. The main reasons for the rating include: 1) the size of the injection/puncture market is growing steadily, and overseas ex
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.